A multicenter, multinational Phase 3 Casppian study will evaluate the efficacy and safety of leuprolide mesylate (FP-001) 42 mg controlled-release in patients with CPP. Gonadotropin-releasing ...

This crystalline arthritis is caused by calcium pyrophosphate (CPP) crystal deposition ... with CPPD disease. The study was carried out in the Million Veterans Program, comprising more than ...

Kevin Sorensen, the junior finance minister, had been critical of efforts by the provinces to expand CPP benefits, quoting from the study when ... benefits of voluntary programs created by the ...

Debiopharm Group™ has announced that it has completed the recruitment of patients for its Phase III clinical study in Central Precocious Puberty (CPP) with triptorelin 22.5 mg. Debiopharm is ...